Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Company Overview

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with life-threatening autoimmune diseases and those undergoing organ or cell transplantation. The company’s research is centered on the CD40 ligand (CD40L) pathway, an important regulator of immune-system activation.

Eledon’s lead product candidate is tegoprubart, an investigational monoclonal antibody designed to block CD40L and reduce harmful immune responses. The company is evaluating tegoprubart in transplant-related settings, including kidney transplantation, as well as in other potential applications involving immune-mediated disease and cell transplantation.

The company was formerly known as Novus Therapeutics and adopted the Eledon Pharmaceuticals name as it shifted its strategic focus toward immunology and transplantation. Eledon is headquartered in Irvine, California, and operates primarily through research, clinical development and collaborations related to its therapeutic programs. David de Graaf serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $2.42 to $2.56
• 50-Day Range: $2.42 to $3.77
• 52-Week Range: $1.35 to $4.60
• Volume: 817,228 shs
• Average Volume: 823,924 shs
• Market Capitalization: $201.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Eledon Pharmaceuticals Stock Analysis - MarketRank™

Eledon Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat, and ranked 764th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Eledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Eledon Pharmaceuticals has a consensus price target of $10.00, representing about 303.2% upside from its current price of $2.48.

Amount of Analyst Coverage

Eledon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eledon Pharmaceuticals is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eledon Pharmaceuticals is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eledon Pharmaceuticals has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.68% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 8.83.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently decreased by 4.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eledon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eledon Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ELDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of Eledon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELDN
• CIK: 1404281
• Web: www.eledon.com
• Phone: (949) 238-8090
• Fax: N/A
• Employees: 33
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Eledon Pharmaceuticals: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +303.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.62 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -149.63%
• Return on Assets: -50.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.90
• Quick Ratio: 7.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 1.84

Miscellaneous

• Outstanding Shares: 81,260,000
• Free Float: 73,460,000
• Market Cap: $201.52 million
• Optionable: Optionable
• Beta: 0.84